March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Evaluation Of Doxorubicin Loaded Mepeg-pcl Nanoparticle For Prevention Of Posterior Capsular Opacification
Author Affiliations & Notes
  • Aditya Konar
    IICB, Kolkata, India
  • Rajdeep Guha
    IICB, Kolkata, India
  • Sushovan Chowdhary
    IICB, Kolkata, India
  • Himangshu Palui
    Veterinary Surgery & Radiology,
    West Bengal University of Animal & Fishery Sciences, Kolkata, India
  • Akhilesh Mishra
    Veterinary Pharmacology & Toxicology,
    West Bengal University of Animal & Fishery Sciences, Kolkata, India
  • Geeta K. Vemuganti
    Dean, School of Medical Sciences, University of Hyderabad, Hyderabad, India
  • Samar Basak
    Eye Bank, Disha Eye Hospital, Barrackpore, India
  • Tapan K. Mandal
    Veterinary Pharmacology & Toxicology,
    West Bengal University of Animal & Fishery Sciences, Kolkata, India
  • Sarbani Hazra
    Veterinary Surgery & Radiology,
    West Bengal University of Animal & Fishery Sciences, Kolkata, India
  • Footnotes
    Commercial Relationships  Aditya Konar, None; Rajdeep Guha, None; Sushovan Chowdhary, None; Himangshu Palui, None; Akhilesh Mishra, None; Geeta K. Vemuganti, None; Samar Basak, None; Tapan K. Mandal, None; Sarbani Hazra, None
  • Footnotes
    Support  Department of Biotechnology,Govt of India
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6912. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Aditya Konar, Rajdeep Guha, Sushovan Chowdhary, Himangshu Palui, Akhilesh Mishra, Geeta K. Vemuganti, Samar Basak, Tapan K. Mandal, Sarbani Hazra; Evaluation Of Doxorubicin Loaded Mepeg-pcl Nanoparticle For Prevention Of Posterior Capsular Opacification. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6912.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Cytotoxic drugs are potent candidate for prevention of posterior capsular opacification (PCO) but toxicity to the intra ocular structures remain a major concern. The purpose of the present study was to prepare and characterize doxorubicin loaded MePEG-PCL nano particle and evaluate its effect on PCO formation. Aqueous availability of doxorubicin and toxicity to intra ocular structures following nanoparticle mediated delivery of the drug.

Methods: : PEG-PCL nanodoxorubicin was prepared and characterized for surface morphology, particle size, zeta potential and distribution of drug within the nanoparticle. Cellular effects of nano doxorubicin on cultured lens epithelial cells were compared with free drug. Lensectomy was performed in one eye of rabbits followed by subconjunctival injection of doxorubicin nanoparticles. The availability of doxorubicin in aqueous was determined by HPLC. PCO formation was evaluated by slit lamp biomicroscopy, Miyake apple posterior view and histopathology. The toxicity on intraocular structures was evaluated by tonometry, specular microscopy, and histopathology

Results: : TEM and AFM showed smooth surface of the nanoparticles and confocal microscopy showed presence of doxorubicin within the particles. Particle size and zeta potential were 92.85 nm and 36.5 mV respectively as determined by DLS. Time of cellular entry of doxorubicin nanoparticles did not differ from the free drug but in former case drug retention within the cell prolonged and cytotoxic effect on LEC increased significantly. Sustained release of doxorubicin was detectable in the aqueous humor. There was significant decrease in PCO in the treated eye, compared to untreated operated eye and no toxicity was observed on intraocular structures following use of nanodoxorubicin

Conclusions: : The use of MePEG-PCL doxorubicin by subconjunctival route can prevent PCO without inciting ocular toxicity.

Keywords: cataract • apoptosis/cell death • cell survival 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×